FIELD: medicine.
SUBSTANCE: invention involves compositions of lamotrigine and its pharmaceutically acceptable derivative of prolonged release. Composition includes: 1) nucleus with lamotrigine or its pharmaceutically acceptable derivative; 2) outer coating of nucleus thickness of which is selected so that it is actually resistant for ambient liquids and actually resistant for release of lamotrigine or its pharmaceutically acceptable derivative, and 3) mentioned outer coating has one or more pores from outer face of coating through essentially all the coating without penetration to mentioned nucleus enabling release of lamotrigine or its pharmaceutically acceptable derivative from nucleus into ambient liquid. Mentioned pores have area or integrated area from approximately 10 to approximately 60% of front-face area of mention composition. And release of lamotrigine or its pharmaceutically acceptable derivative is performed essentially trough mentioned pores. Outer surface at that dissolves in the event ambient pH exceeds 5. Composition provides prolonged release of lamotrigine by two procedures: slower release due to initial release of lamotrigine through the pore, and faster release in further step due to dissolving of outer coating.
EFFECT: elimination of side effects accompanying lamotrigine-based or its pharmaceutically acceptable derivatives therapy.
5 cl, 7 dwg, 9 tbl, 6 ex
